1
|
Simpson SG, Rochford S, Livingstone A, English S, Austin C. Tele‐web Psychology in Rural South Australia: The Logistics of Setting Up a Remote University Clinic Staffed by Clinical Psychologists in Training. AUSTRALIAN PSYCHOLOGIST 2020. [DOI: 10.1111/ap.12049] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
| | - Shirley Rochford
- Rural and Remote Network, Country Health SA Mental Health Service,
| | | | | | - Carly Austin
- Psychology Clinic, University of South Australia,
| |
Collapse
|
2
|
Iwamiya T, Segard BD, Matsuoka Y, Imamura T. Human cardiac fibroblasts expressing VCAM1 improve heart function in postinfarct heart failure rat models by stimulating lymphangiogenesis. PLoS One 2020; 15:e0237810. [PMID: 32936824 PMCID: PMC7494079 DOI: 10.1371/journal.pone.0237810] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Accepted: 08/02/2020] [Indexed: 02/07/2023] Open
Abstract
Cardiovascular diseases are a leading cause of death worldwide. After an ischemic injury, the myocardium undergoes severe necrosis and apoptosis, leading to a dramatic degradation of function. Numerous studies have reported that cardiac fibroblasts (CFs) play a critical role in heart function even after injury. However, CFs present heterogeneous characteristics according to their development stage (i.e., fetal or adult), and the molecular mechanisms by which they maintain heart function are not fully understood. The aim of this study is to explore the hypothesis that a specific population of CFs can repair the injured myocardium in heart failure following ischemic infarction, and lead to a significant recovery of cardiac function. Flow cytometry analysis of CFs defined two subpopulations according to their relative expression of vascular cell adhesion molecule 1 (VCAM1). Whole-transcriptome analysis described distinct profiles for these groups, with a correlation between VCAM1 expression and lymphangiogenesis-related genes up-regulation. Vascular formation assays showed a significant stimulation of lymphatic cells network complexity by VCFs. Injection of human VCAM1-expressing CFs (VCFs) in postinfarct heart failure rat models (ligation of the left anterior descending artery) led to a significant restoration of the left ventricle contraction. Over the course of the experiment, left ventricular ejection fraction and fractional shortening increased by 16.65% ± 5.64% and 10.43% ± 6.02%, respectively, in VCF-treated rats. Histological examinations revealed that VCFs efficiently mobilized the lymphatic endothelial cells into the infarcted area. In conclusion, human CFs present heterogeneous expression of VCAM1 and lymphangiogenesis-promoting factors. VCFs restore the mechanical properties of ventricular walls by mobilizing lymphatic endothelial cells into the infarct when injected into a rat heart failure model. These results suggest a role of this specific population of CFs in the homeostasis of the lymphatic system in cardiac regeneration, providing new information for the study and therapy of cardiac diseases.
Collapse
Affiliation(s)
- Takahiro Iwamiya
- Research & Development Department, Metcela Inc., Kawasaki, Kanagawa, Japan
- Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan
- * E-mail:
| | | | - Yuimi Matsuoka
- Research & Development Department, Metcela Inc., Kawasaki, Kanagawa, Japan
| | - Tomomi Imamura
- Research & Development Department, Metcela Inc., Kawasaki, Kanagawa, Japan
| |
Collapse
|
3
|
Zhang HY, Yang DP, Tang GY. Multipotent antioxidants: from screening to design. Drug Discov Today 2006; 11:749-54. [PMID: 16846803 DOI: 10.1016/j.drudis.2006.06.007] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2006] [Revised: 05/08/2006] [Accepted: 06/09/2006] [Indexed: 12/25/2022]
Abstract
Free-radicals play an important role in the pathogenesis of many diseases, accounting for continuing interest in the identification and development of novel antioxidants that prevent radical-induced damage. To develop more-powerful weapons that address complex diseases in which free-radicals might be significant, but not exclusive drivers, antioxidants that also have other pharmacological effects are desired. To obtain multipotent antioxidants, one can screen drug collections and/or natural-product libraries, or couple an antioxidant group with other pharmacophores. It is interesting to note that most rationally designed multifunctional antioxidants are structurally different from their naturally occurring counterparts. Therefore, nature's design strategy provides important clues as to how the design concept for multipotent antioxidants can be improved.
Collapse
Affiliation(s)
- Hong-Yu Zhang
- Shandong Provincial Research Center for Bioinformatic Engineering and Technique, Center for Advanced Study, Shandong University of Technology, Zibo 255049, P.R. China
| | | | | |
Collapse
|
4
|
Adachi Y, Suzuki Y, Hatanaka T, Fukazawa M, Tamura K. The long-lasting anti-anginal effects of CP-060S in a rat model of arginine vasopressin-induced myocardial ischaemia. J Pharm Pharmacol 2002; 54:413-8. [PMID: 11902808 DOI: 10.1211/0022357021778484] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The anti-anginal effect of CP-060S, a new cardioprotective agent that prevents myocardial Na+-, Ca2+-overload and has Ca2+-channel blocking activity, was evaluated in a rat model of arginine8-vasopressin (AVP)-induced cardiac ischaemia. Infusion of AVP (0.2 IU kg(-1)) depressed the electrocardiogram (ECG) ST segment, an index of myocardial ischaemia. Vehicle, CP-060S and diltiazem were given orally 1, 2, 4, 8, 12 and 24 h before the administration of AVP. CP-060S, at 3 mg kg(-1) and 10 mg kg(-1), suppressed AVP-induced ST-segment depression for 2 h and 12 h, respectively. In contrast, diltiazem, at 10 and 30 mg kg(-1), suppressed AVP-induced ST-segment depression for only 1 h. The persistent suppression of the AVP-induced ST-segment depression by CP-060S correlated with the time course of changes in its plasma concentration. The minimum effective concentration of CP-060S was estimated to be 30 ng mL(-1) (approximately 50 nM), consistent with its vasorelaxant potency in rat isolated aortic strips (concentration producing 50% relaxation of KCl contraction, IC50 = 32.6+/-8.3 nM). Intravenously administered CP-060S, at 300 microg kg(-1) and diltiazem at 500 microg kg(-1) showed similar haemodynamic changes, whereas CP-060S, at 300 microg kg(-1), significantly suppressed AVP-induced ST-segment depression and diltiazem, at 500 microg kg(-1), had no effect on AVP-induced ST-segment depression. In summary, orally administered CP-060S exerted a long-lasting anti-anginal effect proportionate to the time course of changes in its plasma concentration in a rat model of AVP-induced ischaemia.
Collapse
Affiliation(s)
- Yuichiro Adachi
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd, Gotemba-shi, Shizuoka, Japan
| | | | | | | | | |
Collapse
|
5
|
Fukazawa M, Adachi Y, Akima M, Imagawa JI, Suzuki Y, Kuromaru O, Tamura K. Effects of CP-060S, a novel cardioprotective drug, in the methacholine-induced ECG change model in rats. Fundam Clin Pharmacol 2001; 15:135-42. [PMID: 11468023 DOI: 10.1046/j.1472-8206.2001.00014.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We compared the antianginal effect of CP-060S, a novel cardioprotective drug with Na+ and Ca2+ overload-preventing activity as well as Ca2+ channel antagonistic activity, with that of diltiazem, in an experimental model of vasospastic angina induced by methacholine in anaesthetized rats. Intra-aortic injection of methacholine at the coronary ostium provoked the ST-segment elevation of the electrocardiogram (ECG), indicating myocardial ischemia. CP-060S (3, 5 and 10 mg/kg, i.d.) significantly and dose-dependently suppressed the methacholine-induced ST-elevation, with the duration of action being at least 3 h at the highest dose. In addition, CP-060S at 3 mg/kg could inhibit the ST-elevation without producing significant changes in blood pressure, heart rate or rate-pressure product (RPP). In contrast, diltiazem (10 and 30 mg/kg, i.d.) significantly decreased the RPP, a significant suppression of the ST-elevation could only be achieved at the highest dose and its duration of action was about 2 h. Similar results were obtained with i.v. administration of the drugs, i.e. CP-060S given i.v. could inhibit the ST-elevation with less haemodynamic changes than diltiazem. In conclusion, CP-060S exerted a more potent and sustained protection against myocardial ischemia evoked by methacholine than diltiazem. The characteristics of the effects of CP-060S observed here suggest that this drug may be a desirable drug for the treatment of vasospastic angina.
Collapse
Affiliation(s)
- M Fukazawa
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotembashi, Shizuoka 412-8513, Japan.
| | | | | | | | | | | | | |
Collapse
|
6
|
Kato T, Ozaki T, Tsuzuki K, Ohi N. Practical Synthesis of Novel Cardioprotective Drug, CP-060S. Org Process Res Dev 2000. [DOI: 10.1021/op000096h] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Tatsuya Kato
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Company, Ltd., 135, 1-Chome Komakado, Gotemba City, Shizuoka 412-8513, Japan
| | - Tomokazu Ozaki
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Company, Ltd., 135, 1-Chome Komakado, Gotemba City, Shizuoka 412-8513, Japan
| | - Kouichi Tsuzuki
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Company, Ltd., 135, 1-Chome Komakado, Gotemba City, Shizuoka 412-8513, Japan
| | - Nobuhiro Ohi
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Company, Ltd., 135, 1-Chome Komakado, Gotemba City, Shizuoka 412-8513, Japan
| |
Collapse
|
7
|
Hara A, Suzuki T, Hashizume H, Shishido N, Nakamura M, Ushikubi F, Abiko Y. Effects of CP-060S, a novel Ca(2+) channel blocker, on oxidative stress in cultured cardiac myocytes. Eur J Pharmacol 1999; 385:81-8. [PMID: 10594347 DOI: 10.1016/s0014-2999(99)00708-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The effect of (-)-(S)-2-[3,5-bis(1, 1-dimethylethyl)-4-hydroxyphenyl]-3-[3-[N-methyl-N-[2-(3, 4-methylenedioxyphenoxy)ethyl]amino]propyl]-1,3-thiazolidin- 4-one hydrogen fumarate (CP-060S), a novel Ca(2+) channel blocker, on hydrogen peroxide (H(2)O(2))-induced cytotoxicity was studied in cultured rat cardiac myocytes. The CP-060S effect was compared with that of CP-060R, an optical isomer of CP-060S with a less potent Ca(2+) channel blocking action than CP-060S. H(2)O(2) increased the release of lactate dehydrogenase from cardiac myocytes and decreased the formation of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (MTT) formazan in cardiac myocytes (i.e., cytotoxic action). Both CP-060S (1 microM) and CP-060R (1 microM) attenuated to a similar extent the foregoing alterations induced by H(2)O(2). On the other hand, 1,3-dimethyl-2-thiourea (10 mM), a scavenger of both H(2)O(2) and hydroxyl radical, also attenuated the H(2)O(2)-induced cytotoxicity whereas diltiazem (10 microM) did not. In an experiment using electron spin resonance (ESR) with 5, 5-dimethyl-1-pyrroline N-oxide (DMPO), a spin-trapping agent, both CP-060S and CP-060R decreased the intensity of DMPO-hydroxyl radical signal concentration dependently. These results suggest that CP-060S protects cardiac myocytes from oxidative stress through its radical scavenging action.
Collapse
Affiliation(s)
- A Hara
- Department of Pharmacology, Asahikawa Medical College, Asahikawa, Japan
| | | | | | | | | | | | | |
Collapse
|
8
|
Kato T, Ozaki T, Tamura K, Suzuki Y, Akima M, Ohi N. Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 2. Structure-activity relationships of thiazolidinone derivatives. J Med Chem 1999; 42:3134-46. [PMID: 10447958 DOI: 10.1021/jm9900927] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
CP-060 (1), 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-[3-[N-methyl-N-[2-[3, 4-(methylenedioxy)phenoxy]ethyl]amino]propyl]-1,3-thiazolidin-4-on e, is a novel type of Ca(2+) antagonist possessing both Ca(2+) overload inhibition and antioxidant activity. The structure-activity relationships for this series of compounds were studied by synthesizing the analogues and evaluating these three kinds of activity. Ca(2+) antagonistic activity was largely determined by the lipophilicity of the phenyl group at the 2-position and the length of the alkyl chains. As for the antioxidant activity, it was demonstrated that the phenolic hydroxyl group is an essential structural element. Compounds with potent activity were evaluated for their effect on the coronary blood flow in vivo. Among these compounds, compound 1 was shown to be the most potent. Furthermore, the enantiomers of 1 were resolved by high-performance liquid chromatography with a chiral column. Compound (-)-1 showed about 10 times higher Ca(2+) antagonistic activity than (+)-1, though both enantiomers had similar potency in Ca(2+) overload inhibition and antioxidant activity. An X-ray crystal structure determination of (-)-1 hydrogen fumarate identified (-)-1 as having S configuration at the 2-position.
Collapse
MESH Headings
- Animals
- Antioxidants/chemical synthesis
- Antioxidants/chemistry
- Antioxidants/pharmacology
- Aorta/drug effects
- Aorta/metabolism
- Calcium/antagonists & inhibitors
- Calcium Channels/metabolism
- Calcium Channels, L-Type
- Chromatography, High Pressure Liquid
- Coronary Circulation/drug effects
- Crystallography, X-Ray
- Dogs
- In Vitro Techniques
- Lipid Peroxidation/drug effects
- Lipoproteins, LDL/chemistry
- Lipoxygenase/chemistry
- Male
- Models, Molecular
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Myocardium/cytology
- Myocardium/metabolism
- Phenols/chemical synthesis
- Phenols/chemistry
- Phenols/pharmacology
- Rabbits
- Rats
- Rats, Sprague-Dawley
- Glycine max/chemistry
- Stereoisomerism
- Structure-Activity Relationship
- Thiazoles/chemical synthesis
- Thiazoles/chemistry
- Thiazoles/pharmacology
- Thiazolidines
Collapse
Affiliation(s)
- T Kato
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Company, Ltd., 135, 1-Chome Komakado, Gotemba City, Shizuoka 412-8513, Japan
| | | | | | | | | | | |
Collapse
|
9
|
Adachi Y, Suzuki Y, Homma N, Fukazawa M, Tamura K, Nishie I, Kuromaru O. The anti-ischemic effects of CP-060S during pacing-induced ischemia in anesthetized dogs. Eur J Pharmacol 1999; 367:267-73. [PMID: 10079001 DOI: 10.1016/s0014-2999(98)00938-8] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
CP-060 S, (-)-( S)-2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-3-[3-[N-methyl-N-[2-(3 ,4-methylenedioxyphenoxy)ethyl]-amino]propyl]-1,3-thiazolidin++ +-4-one hydrogen fumarate, is a novel cardioprotective drug which prevents Na+-, Ca2+-overload and has Ca2+ channel blocking activity. We compared the anti-ischemic effects of CP-060S with those of diltiazem, a Ca2+ channel blocker, and R56865, N-[1-[4-(4-fluorophenoxy)butyl]-4-piperidinyl]-N-methyl-2-benzothiazo lamine, a Na+-, Ca2+-overload inhibitor, in a canine pacing-induced ischemia model. CP-060S 100 microg kg(-1) significantly suppressed the pacing-induced ischemic epicardial ST-segment elevation by maximally 75%, while diltiazem 100 microg kg(-1) suppressed it by maximally 35%. R56865 100 microg kg(-1) significantly suppressed the ST-segment elevation by maximally 30%. In addition, diltiazem 100 microg kg(-1) caused synergistic suppression of ST-segment elevation by 70% when administered simultaneously with R56865 100 microg kg(-1). These results suggest that a Na+-, Ca2+-overload preventive action and a Ca2+ channel blocking action independently contribute to the suppression of the ST-segment elevation. Therefore, CP-060S may suppress pacing-induced ST-segment elevation by a dual action by preventing Na+-, Ca2+-overload and the Ca2+ channel blockade.
Collapse
Affiliation(s)
- Y Adachi
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical, Shizuoka, Japan
| | | | | | | | | | | | | |
Collapse
|
10
|
Suzuki Y, Akima M, Tamura K. Effects of CP-060S, a novel cardioprotective drug, on cardiac function and myocardial oxygen consumption. GENERAL PHARMACOLOGY 1999; 32:57-63. [PMID: 9888255 DOI: 10.1016/s0306-3623(98)00062-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
1. We examined the effects of CP-060S on cardiac function and myocardial oxygen consumption (MVO2) in anesthetized dogs. 2. CP-060S (10-300 microg/kg i.v.) decreased heart rate, increased aortic flow and decreased mean blood pressure in a dose-dependent manner. The PR interval was significantly prolonged by administration of CP-060S (300 microg/kg i.v.). 3. CP-060S (10-300 microg/kg i.v.) increased coronary blood flow in a dose-dependent manner. Left ventricular end-diastolic pressure and maximal first derivative of left ventricular pressure were not significantly affected. 4. CP-060S (10-300 microg/kg i.v.) increased coronary sinus blood flow and decreased arteriovenous oxygen difference and MVO2 in a dose-dependent manner. 5. The effects of CP-060S on cardiac function and MVO2 are qualitatively similar to those of diltiazem, a typical Ca2+ antagonist.
Collapse
Affiliation(s)
- Y Suzuki
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan.
| | | | | |
Collapse
|
11
|
Sugiyama A, Hashimoto K. Antiischemic effects of CP-060S, an inhibitor of pathologically modified sodium channels, assessed in the canine experimental model of angina pectoris. J Cardiovasc Pharmacol 1999; 33:70-7. [PMID: 9890399 DOI: 10.1097/00005344-199901000-00011] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
CP-060S is a novel compound that can inhibit the slow inward calcium current as well as the veratridine-induced, noninactivating sodium current. Antiischemic and cardiovascular effects of CP-060S were assessed by using halothane-anesthetized beagle dogs and compared with the effects of semotiadil, a benzothiazine calcium antagonist. The first or second diagonal branch was narrowed. ECG, unipolar electrograms from both ischemic and nonischemic regions, and systemic and left ventricular pressure were monitored. The left ventricle was electrically driven at 190-240 beats/min for 3 min to induce reversible myocardial ischemia. The severity of ischemia was judged by the magnitude of ST-segment depression. CP-060S (0.1 mg/kg, i.v.) significantly attenuated the pacing-induced ST-segment depression in the ischemic region >2 h, whereas during the sinus rhythm, it showed reversible negative chronotropic, inotropic, and dromotropic effects and induced transient depressor response, which would not necessarily be considered favorable (n = 8). A smaller dose of CP-060S (0.03 mg/kg, i.v.) showed a similar antiischemic and cardiovascular profile, but each effect was less potent than that of the higher dose (n = 7). Semotiadil (0.1 and 0.3 mg/kg, i.v.) also showed cardiovascular suppression similar to that of CP-060S; however, the antiischemic effect was not detected during the whole experimental period (n = 6). Thus the inhibition of the noninactivating sodium current may be the primary reason for the antiischemic effect of CP-060S and could become a new cytoprotective principle in the treatment of patients with ischemic heart disease.
Collapse
Affiliation(s)
- A Sugiyama
- Department of Pharmacology, Yamanashi Medical University, Nakakoma, Japan
| | | |
Collapse
|
12
|
Kato T, Ozaki T, Tamura K, Suzuki Y, Akima M, Ohi N. Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)thiazolidinones. J Med Chem 1998; 41:4309-16. [PMID: 9784106 DOI: 10.1021/jm980335f] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A series of 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)thiazolidinones was synthesized in order to explore novel calcium antagonists with potent antiischemic activity. These compounds were designed to have, in addition to Ca2+ antagonistic activity, both Ca2+ overload prevention and antioxidant activity in one molecule. These three kinds of activity were evaluated by using a K+-depolarized rat aorta, a veratridine-induced Ca2+ overload model of rat cardiomyocytes, and a soybean lipoxygenase-induced lipid peroxidation model of rabbit low-density lipoprotein, respectively. In particular, 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-[3-[N-methyl-N-[2-[3, 4-(methylenedioxy)phenoxy]ethyl]amino]propyl]-1,3-thiazolidin-4-on e (7o) was found to be highly potent and possessed a well-balanced combination of these actions in vitro.
Collapse
Affiliation(s)
- T Kato
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Company, Ltd., 135, 1-Chome Komakado, Gotemba City, Shizuoka 412-8513, Japan
| | | | | | | | | | | |
Collapse
|
13
|
Suzuki Y, Tamura K, Adachi Y, Fukazawa M, Kato T. CP-060S interacts with three principal binding sites on the L-type Ca2+ channel. Eur J Pharmacol 1998; 342:347-51. [PMID: 9548407 DOI: 10.1016/s0014-2999(97)01496-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
CP-060S, (-)-(S)-2-[3,5-bis(1,1-dimethylethyl)-4-hydroxypheny1]-3-[3-[N-met hyl-N-[2-(3,4-methylenedioxyphenoxy)ethyl]amino]propyl]-1,3-thi azolidin-4-one hydrogen fumarate is a novel cardioprotective drug, which is able to prevent Na+-, Ca2+-overload and also has Ca2+ channel blocking activity. The latter action of CP-060S was characterized by radioligand binding experiments with rat cardiac membranes in terms of the interaction with the three principal binding sites on the L-type Ca2+ channel, which bind such drugs as the 1,4-dihydropyridines, phenylalkylamines and benzothiazepines. CP-060S exhibited complete and concentration-dependent inhibition of [3H](+)-PN200-110, [3H](-)-desmethoxyverapamil and [3H]cis-(+)-diltiazem binding to their specific binding sites. Saturation studies showed that CP-060S increased the Kd of [3H](+)-PN200-110 and [3H](-)-desmethoxyverapamil without causing a significant change in the maximum binding density. The dissociation kinetics of the three radioligands were accelerated by CP-060S. These results suggest that CP-060S interacts with a novel binding site on the L-type Ca2+ channel and has a negative allosteric interaction with the three principal binding sites for the 1,4-dihydropyridines, phenylalkylamines and benzothiazepines.
Collapse
Affiliation(s)
- Y Suzuki
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan.
| | | | | | | | | |
Collapse
|